Amarin (AMRN) Vascepa NCE Not in Latest FDA Orange Book Update
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin's (Nasdaq: AMRN) Vascepa NCE is not in the latest U.S. FDA Orange Book update. To visit the FDA page, click here.
Shares are down 0.4 percent Friday.
Shares are down 0.4 percent Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genmab's Rina-S shows 45.9% response rate in ovarian cancer trial
- Evaxion to present EVX-01 cancer vaccine immune data at SITC 2026
- Vera Therapeutics to present ORIGIN 3 trial data at ASN Kidney Week
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
